Nordic MuBio

Mouse anti CD68 (Macrosialin) conjugated to FITC

Product Code:
 
GM-4152
Product Group:
 
Primary Antibodies
Supplier:
 
Nordic MuBio
Host Type:
 
Mouse
Antibody Isotype:
 
IgG1
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
Ki-M7
Regulatory Status:
 
RUO
Target Species:
 
Human
Application:
 
Flow Cytometry
Storage:
 
Nordic-MUbio monoclonal antibody reagents contain optimal concentrations of affinity-purified antibody. For stability reasons this monoclonal antibody solution contains sodium azide. These reagents should be stored at 2-8°C (DO NOT FREEZE!) and protec
1 / 2
2 / 2

No additional charges, what you see is what you pay! *

CodeSizePrice
GM-41522ml (100 Tests)£360.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Netherlands.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Applications Description:
Permeabilization and Staining Procedure
- In combination with our Permeabilization Kit FIX&PERM? (Cat. No. GAS-002) intracellular CD68 can be easily stained in cell suspensions.
- For each sample to be analyzed add 50 ?l of whole blood, bone marrow or mononuclear cell suspension in a 5ml tube
- Add 100 ?l of Reagent A (Fixation Medium, stored and used at room temperature)
- Incubate for 15 minutes at room temperature
- Add 5 ml phosphate buffered saline and centrifuge cells for 5 minutes at 300 g
- Remove supernatant and add to cell pellet 100?l Reagent B (Permeabilization Medium) and 20 ?l of the CD68 monoclonal antibody conjugate
- Vortex at low speed for 1-2 seconds
- Incubate for 15 minutes at room temperature
- Wash cells with phosphate buffered saline as described above
- Remove supernatant and resuspend cells in sheath fluid for immediate analysis or resuspend cells in 0.5 ml 1.0 %
formaldehyde and store them at 2-8°C in the dark. Analyze fixed cells within 24 hours
Background:
CD68 (macrosialin) is a type-one membrane protein with significant sequence homology to a family of lysosomal-associated glycoproteins (lamp). CD68 molecules are predominantly located
intracellularily in cytoplasmic granules but can also be detected in smaller amounts at the cell surface. Particular strong intracellular expression is observed for monocytes and macrophages. In
addition, Langerhans cells as well as plasmacytoid dendritic cells express clear-cut levels of CD68. Low-level reactivity is also observed with a subset of B lymphocytes and activated T lymphocytes. Oxidized low-density lipoprotein is a ligand for CD68.

The CD68 mAb permits the identification and enumeration of monocytes, Langerhans cells and plasmacytoid dendritic cells (in combination with CD4/CD56 staining) in normal and malignant human blood and bone marrow samples using flow cytometry. Results must be put within the context of other diagnostic tests as well as the clinical history of the patient by a certified professional before final interpretation. Analyses performed with this antibody should be paralleled by positive and negative controls. If unexpected results are obtained which cannot be attributed to differences in laboratory procedures, please contact us.
Caution:
For professional users only.
This reagent contains sodium azide. To avoid the development
of hazardous conditions, reagents containing azide should be
diluted in running water prior to be discarded. Similar to the work
with other biological products, proper handling procedures are
recommended.
Formulation:
Purified by Chromatography, Storage buffer: PBS pH 7.2, 1% BSA, 0.05% NaN3
Label:
FITC
Product:
Purified by Chromatography, Storage buffer: PBS pH 7.2, 1% BSA, 0.05% NaN3
Product Form:
FITC
Purification Method:
Purified by Chromatography
Specificity:
The CD68 mAb (clone Ki-M7) reacts with human macrosialin.

The sensitivity of CD68 mAb is determined by staining well-defined blood samples from representative donors with serial-fold mAb dilutions to obtain a titration curve that allows relating the mAb concentration to the percentage of stained cells and geometric MFI (mean fluorescence intensity). For this purpose, a mAb concentration range is selected to include both the saturation point (i.e. the mAb dilution expected to bind all epitopes on the target cell) and the detection threshold (i.e. the mAb dilution expected to represent the least amount of mAb needed to detect identical percentage of cells). In practice, 50?l of leukocytes containing 10^7 cells/ml are stained with 20?l mAb of various dilutions to obtain a titration curve and to identify the saturation point and detection threshold. The final concentration of the product is then adjusted to be at least 3-fold above the detection threshold. In addition and to control lot-to-lot variation, the given lot is compared and adjusted to fluorescence standards with defined intensity.
UniProt:
P34810

References

1. Davey, F. R., Cordell, J. L., Erber, W. N., Pulford, K. A., Gatter, K. C. & Mason, D. Y. (1988) J Clin Pathol 41, 753-8.
2.
Feuillard, J., Jacob, M. C., Valensi, F., Maynadie, M., Gressin, R., Chaperot, L., Arnoulet, C., Brignole-Baudouin, F., Drenou, B., Duchayne, E., Falkenrodt, A., Garand, R., Homolle, E., Husson, B.,
Kuhlein, E., Le Calvez, G., Sainty, D., Sotto, M. F., Trimoreau, F. & Bene, M. C. (2002) Blood 99, 1556-63.

3. Fukuda, M. (1991) J Biol Chem 266, 21327-30.
4.
Holness, C. L. & Simmons, D. L. (1993) Blood 81, 1607-13.
5.
Knapp, W., Strobl, H. & Majdic, O. (1994) Cytometry 18, 187-98.

6. Pulford, K. A., Rigney, E. M., Micklem, K. J., Jones, M., Stross, W. P., Gatter, K. C. & Mason, D. Y. (1989) J Clin Pathol 42, 414-21.
7.
Rabinowitz, S. S. & Gordon, S. (1991) J Exp Med 174, 827-36.
8.
Ramprasad, M. P., Fischer, W., Witztum, J. L., Sambrano, G. R., Quehenberger, O. & Steinberg, D. (1995) Proc Natl Acad Sci U S A 92, 9580-4.
9.
Ramprasad, M. P., Terpstra, V., Kondratenko, N., Quehenberger, O. & Steinberg, D. (1996) Proc Natl Acad Sci U S A 93, 14833-8.
10.
Sadovnikova, E., Parovichnikova, E. N., Savchenko, V. G., Zabotina, T. & Stauss, H. J. (2002) Leukemia 16, 2019-26.

11. Scheinecker, C., Strobl, H., Fritsch, G., Csmarits, B., Krieger, O., Majdic, O. & Knapp, W. (1995) Blood 86, 4115-23.

12. Strobl, H. & Knapp, W. (2004) J Biol Regul Homeost Agents 18, 335-9.
13.
Strobl, H., Scheinecker, C., Csmarits, B., Majdic, O. & Knapp, W. (1995) Br J Haematol 90, 774-82.
14.
Strobl, H., Scheinecker, C., Riedl, E., Csmarits, B., Bello-Fernandez, C., Pickl, W. F., Majdic, O. & Knapp, W. (1998) J Immunol 161, 740-8